



Novel and Personalized Therapies for Multiple Myeloma and Plasma Cell Disorders

Guest Editors:

Dr. Moshe Gatt

Hadassah University Medical
Centre, Jerusalem, Israel

Dr. Efstathios Kastritis

Department of Clinical
Therapeutics, National and
Kapodistrian University of
Athens, Athens, Greece

Deadline for manuscript
submissions:

closed (20 June 2023)

Message from the Guest Editors

Multiple myeloma and other plasma cell dyscrasias are a heterogeneous group of disorders, producing monoclonal proteins that originate from the proliferation of monoclonal plasma cells and cause severe end organ damage, with fatal consequences. The introduction of novel agents and treatment modalities has progressed the field immensely. The availability of more options has led to the need and our ability to individualize the treatment. In this Special Issue, we would like to update the advances in Novel and Personalized Therapies for Multiple Myeloma.

This theme issue is intended to report an overview of newer diagnostic methods and monitoring techniques in diagnosis and to provide an in depth description of specific patient care with newer individualized treatment approaches.

In this Special Issue, original research articles and reviews are welcome. We welcome all types of papers on the broad spectrum of clinical characteristics, laboratory and clinical diagnosis, prognosis, pathophysiology, and treatment of in respect to the Novel and Personalized Therapies for Multiple Myeloma and other plasma cell dyscrasias.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)